PMID- 35366991
OWN - NLM
STAT- MEDLINE
DCOM- 20220405
LR  - 20220601
IS  - 0091-679X (Print)
IS  - 0091-679X (Linking)
VI  - 168
DP  - 2022
TI  - Mouse models of graft-versus-host disease.
PG  - 41-66
LID - S0091-679X(21)00113-8 [pii]
LID - 10.1016/bs.mcb.2021.12.008 [doi]
AB  - Transplantation of allogeneic hematopoietic stem and progenitor cells (allo-HCT) 
      allows for cure of life-limiting malignant and non-malignant hematologic 
      diseases. Crossing the human leukocyte antigen (HLA) barrier, however, comes at 
      the cost of graft-versus-host disease (GVHD), a life-threatening syndrome 
      mediated in part by the same donor T-lymphocytes that eliminate malignant cells. 
      Acute GVHD occurs in the skin, gut, and/or liver in 25-55% of patients with a 
      mortality rate of 15-40%, while chronic GVHD develops in 30-65% of patients who 
      survive at least 3 months following allo-HCT and is highly debilitating in its 
      extensive form, with a 30-50% 5year mortality rate stemming in part from immune 
      dysregulation and opportunistic infections. Knowledge gaps remain in 
      understanding the pathogenesis and in developing novel and effective treatments 
      for the acute and chronic GVHD, which have distinct biology and yet are both 
      treated with front line systemic corticosteroids. Novel and informative mouse 
      models remain the primary means by which these diseases are studied and drugs 
      initially developed prior to testing in humans. In this chapter, we describe 
      allo-HCT mouse models and protocols using these mouse models by which to study 
      acute and chronic GVHD with the goal of improving prevention and therapy.
CI  - Copyright (c) 2022 Elsevier Inc. All rights reserved.
FAU - Patel, Dilan A
AU  - Patel DA
AD  - Bone Marrow Transplantation & Leukemia, Oncology Division, Department of 
      Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO, 
      United States. Electronic address: dpatel1@wustl.edu.
FAU - Schroeder, Mark A
AU  - Schroeder MA
AD  - Bone Marrow Transplantation & Leukemia, Oncology Division, Department of 
      Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO, 
      United States.
FAU - Choi, Jaebok
AU  - Choi J
AD  - Bone Marrow Transplantation & Leukemia, Oncology Division, Department of 
      Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO, 
      United States.
FAU - DiPersio, John F
AU  - DiPersio JF
AD  - Bone Marrow Transplantation & Leukemia, Oncology Division, Department of 
      Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO, 
      United States.
LA  - eng
GR  - P50 CA171963/CA/NCI NIH HHS/United States
GR  - R35 CA210084/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20220117
PL  - United States
TA  - Methods Cell Biol
JT  - Methods in cell biology
JID - 0373334
SB  - IM
MH  - Animals
MH  - Disease Models, Animal
MH  - *Graft vs Host Disease/etiology/pathology
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects/methods
MH  - Humans
MH  - Mice
MH  - T-Lymphocytes
OTO - NOTNLM
OT  - Acute GVHD
OT  - Chronic GVHD
OT  - JAK/STAT
OT  - Modeling
OT  - Spleen
OT  - T-cells
EDAT- 2022/04/04 06:00
MHDA- 2022/04/06 06:00
CRDT- 2022/04/03 20:22
PHST- 2022/04/03 20:22 [entrez]
PHST- 2022/04/04 06:00 [pubmed]
PHST- 2022/04/06 06:00 [medline]
AID - S0091-679X(21)00113-8 [pii]
AID - 10.1016/bs.mcb.2021.12.008 [doi]
PST - ppublish
SO  - Methods Cell Biol. 2022;168:41-66. doi: 10.1016/bs.mcb.2021.12.008. Epub 2022 Jan 
      17.